Erratum to: Serum IgG against *Candida* predict survival in patients with metastatic renal cell carcinoma

Reinhold Ramoner · Andrea Rahm ·
Claudia E. Falkensammer · Nicolai Leonhartsberger ·
Martin Thurnher

Published online: 13 May 2010
© Springer-Verlag 2010

Erratum to: Cancer Immunol Immunother DOI 10.1007/s00262-010-0827-z

Unfortunately the original version has been published without the Conflict of interest statement. Please find below the statement.

Conflict of interest statement Martin Thurnher wishes to disclose that he has a financial interest in Sentimun Biotechnology and that he has filed a patent application that concerns the use of *Candida* IgG for cancer patient prognosis.

The online version of the original article can be found under doi:[10.1007/s00262-010-0827-z](https://doi.org/10.1007/s00262-010-0827-z).

R. Ramoner · A. Rahm · C. E. Falkensammer ·
N. Leonhartsberger · M. Thurnher (✉)
Immunotherapy Unit, Department of Urology,
Innsbruck Medical University, Innrain 66a,
6020 Innsbruck, Austria
e-mail: martin.thurnher@i-med.ac.at

Present Address:

R. Ramoner
Fachhochschule Gesundheit (FHG), Innsbruck, Austria